Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13775)	11/5/2004 12:34:18 PM
From: Montana Wildhack	Respond to of 14101

Dimethaid amends short-term loan agreement TORONTO, Nov. 5 /CNW/ - Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX) has amended its short-term loan arrangement with Dr. F.W. Kuhne, former principal of Oxo Chemie AG. In September 2004, Dr. Kuhne agreed to provide Dimethaid with a short-term loan of approximately $674,000. Dr. Kuhne has agreed to amend the terms of this agreement to convert the loan into common shares of Dimethaid, eliminating the possibility that Dimethaid will be required to repay the full amount of the short-term loan in cash. The loan further provides that if Dr. Kuhne elects to convert his loan to common shares, and the value of the shares on the date of repayment is less than the principal amount of the loan, Dimethaid will be required to pay the differential amount in cash. Under the terms of the amendment, any cash payments associated with the loan will not become due until January 2006, at which time any such payments will be made in 12 equal monthly instalments. Dimethaid has also received an offer of mortgage financing for its Markham head office in the amount of $1,950,000 with interest at 8 3/4 percent per annum and a two percent up front fee. The Company intends to use the proceeds of this mortgage to discharge the current mortgage on the property. The short-term loan cash amount has been subtracted from the current obligations Dimethaid intended to satisfy with the net proceeds of the proposed offering. Accordingly, Dimethaid now anticipates being able to use a greater portion of the proceeds of the proposed offering for clinical trials and general corporate purposes.

To: Cal Gary who wrote (13775)	11/6/2004 1:50:24 PM
From: AlexNewbie	Read Replies (1) \| Respond to of 14101

Thanks Gary, Also I read news that Dr. Kuhne agreed to provide Dimethaid with a short-term loan of approximately $674,000. Dimthaid gave him stock in return. I was wondering if you know at what price he can sell his stock? So the best thing for me is to hold the stock. I was wondering if I had any other questions if I can contact you? I do not see Dimethaid going back up to $.90 anytime soon. I hope you baught the stock at a lot more lower price. Thanks again. If Pennsaid gets approval I can see the stock going up.